Navigation Links
Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association

indications have recently been licensed to Nippon Kayaku, a key player in the Japanese oncology market.

Spectrum is developing ozarelix for benign prostatic hypertrophy (BPH), hormone-dependent prostate cancer and other indications.

About Benign Prostatic Hypertrophy

Benign prostatic hypertrophy is a non-cancerous enlargement of the prostate frequently occurring in men over the age of 50. According to the National Institutes of Health, BPH affects more than 50% of men over the age of 60 and as many as 90% of men over the age of 70 and it is estimated that there are currently more than 28 million men suffering from BPH in the United States.

The IPSS (also known as AUA symptom index) is a standardized scoring system that evaluates the seven principal symptoms of BPH. The enlargement can result in the gradual squeezing of the urethra, resulting in increased frequency or difficulty in urinating. Treatment options for BPH include surgery and medications to reduce the amount of tissue and increase the flow of urine. Current treatment options have limited efficacy, leading to inadequate compliance. Medications currently available belong to two classes: alpha blockers (such as FLOMAX(R)[1], CARDURA(R)[2] and HYTRIN(R)[3]) which relax the muscles in the neck of the bladder and in the prostate, but have no direct effect on the prostate growth itself, and alpha reductase inhibitors (such as PROSCAR(R)[4] and AVODART(R)[5]), which can result in some reduction of the prostate size but have a very slow onset of action, and may be associated with impotence and decreased libido.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals acquires, develops and commercializes a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clin
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/1/2015)... Calif. , May 1, 2015 The ... its 2015 health literacy award winners. The IHA Health ... that make an impact on the practice of educating ... health literacy. IHA gives awards in three categories: innovative ... bestowed its Health Literacy Hero award. In ...
(Date:5/1/2015)... Semler Scientific, Inc. (Nasdaq: SMLR ), ... and markets products that assist healthcare providers in monitoring ... for the first quarter ended March 31, 2015. ... reported continued progress with year over year growth of ... 14%," said Doug Murphy-Chutorian , M.D., chief executive ...
(Date:5/1/2015)... -- Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) ... results of the Phase 3 Rocket 1 trail of ... to meet its end points, compelling data from the ... studies. An analyst report on AERI that ... analyst summary, valuation, and recommendation can be viewed by ...
Breaking Medicine Technology:Institute for Healthcare Advancement Announces 2015 Award Winners 2Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2
... FARMINGDALE, N.Y., Feb. 9, 2011 Misonix, Inc. ... company that designs, manufactures, and markets innovative, therapeutic, ... neurosurgery, laparoscopic surgery, and other surgical and medical ... fiscal quarter and six months ending December 31, ...
... SAN FRANCISCO, Feb. 9, 2011 SYNARC, ... to the pharmaceutical and biotechnology industries, announced today that ... and marketing efforts in support of the company,s rapidly ... Ciaran Cooper, a pioneer in the clinical trials ...
Cached Medicine Technology:Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 2Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 3Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 4Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 5Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 6SYNARC Appoints Ciaran Cooper as Vice President, Business Development 2
(Date:5/2/2015)... May 03, 2015 As one of ... the prestigious Safety and Health Achievement and Recognition Program ... to be chosen by the Illinois Department of Labor ... achieved and maintained SHARP certification by the Occupational Safety ... as Essentra has continued to meet or exceed all ...
(Date:5/2/2015)... Vancouver fencing company, QS Fencing, has recently announced ... prospective clients related to their questions on railings and gates. ... their decks and patios. While that seems like an easy ... the person rolls up their sleeve to start working. One ... finding a gate that matches it. , Instead of spending ...
(Date:5/2/2015)... Aliso Viejo, CA (PRWEB) May 02, 2015 ... made exclusively for use in Final Cut Pro X. ... ready for use in Final Cut Pro X . ... a single keyframe with Pixel Film Studios' ProText Kinetic 2. ... drop. Start by staggering two ProText Kinetic presets in ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 We are ... The Delray Recovery Center as one of the Top ... known in the addiction treatment field for their ethics ... to innovate and to continue their educational efforts. The ... workplace environment, never forgetting their purpose – to help ...
(Date:5/2/2015)... On Tuesday April 7th, the patient ... to celebrate improvements in patient care. In 2014 the ... had zero acquired ventilator associated infections, zero central line ... was also recently named a Top Performer by the ... credited the teamwork of staff from all departments involved ...
Breaking Medicine News(10 mins):Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2
... Medicare ... ... -- If you’re one of the more than 45 million people relying on Medicare for ... is too expensive, according to Allsup , a nationwide provider of Social Security disability ...
... , , , ... NXTM ), a leading manufacturer of innovative dialysis products, today ... Chief Financial Officer, will be presenting at the UBS Global Life ... Grand Central in New York City. , , ...
... , , BIRMINGHAM, Ala., ... leader in radiology optimization solutions that increase business capacity, productivity ... its Board of Directors has approved changing its name to ... its ability to more accurately represent the precision imaging management ...
... , , FRANKLIN LAKES, N.J., Sept. 1 BD ... that it would present at the following investor healthcare conferences in September: , , ... September 9, 2009, 10:55 ... September 14, 2009, ...
... rank facilities don,t take all measurements into account , TUESDAY, ... onto the U.S. News & World Report list ... in some measurements regarding heart failure, researchers say. , "If ... the areas of heart failure mortality and readmission, you should ...
... , PISCATAWAY, N.J., Sept. 1 Milestone ... advanced injection technologies, today announced that Leslie Bernhard, an independent ... Osser who had previously led the Company as Chairman since ... Chief Executive Officer since February 2009 and was formerly Milestone,s ...
Cached Medicine News:Health News:Allsup Outlines 10 Critical Questions to Answer When Evaluating Medicare Plans 2Health News:Allsup Outlines 10 Critical Questions to Answer When Evaluating Medicare Plans 3Health News:Allsup Outlines 10 Critical Questions to Answer When Evaluating Medicare Plans 4Health News:Allsup Outlines 10 Critical Questions to Answer When Evaluating Medicare Plans 5Health News:NxStage to Present at the UBS Global Life Sciences Conference 2Health News:Optimal Readings Completes Strategic Name Change to Optimal IMX 2Health News:Optimal Readings Completes Strategic Name Change to Optimal IMX 3Health News:Optimal Readings Completes Strategic Name Change to Optimal IMX 4Health News:Optimal Readings Completes Strategic Name Change to Optimal IMX 5Health News:Optimal Readings Completes Strategic Name Change to Optimal IMX 6Health News:Government Best Source for U.S. Hospital Data, Study Finds 2Health News:Milestone Scientific Announces Key Leadership Changes 2Health News:Milestone Scientific Announces Key Leadership Changes 3
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
... collagen hemostat. FirstStop is a non-friable, non-woven ... characteristics. It can easily be cut to ... FirstStop products are not dispersed when wet ... hemostasis is achieved. As the collagen forms ...
InterVascular HemaPatch product line offers the vascular surgeon a range of collagen coated patches in a range of larger sizes angioplasty, or profundaplasty procedures without suture hole bleeding. ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: